Beam Therapeutics (BEAM)
NASDAQ:BEAM
Top Page
Beam Therapeutics
(NASDAQ:BEAM)
Select Model
Select Model
Rating:54Neutral
Price Target:
$24.50
▲(1.11% Upside)
Action:ReiteratedDate:03/06/26
BEAM scores in the mid-range primarily because strong balance-sheet positioning and positive, milestone-rich pipeline/financing updates are weighed down by very weak current fundamentals (large losses and significant cash burn). Technical indicators and valuation (negative P/E, no dividend) provide limited additional support.
Positive Factors
Strong cash runway
A large cash balance plus a structured $500M facility materially reduces near-term financing pressure and permits multi-program execution. This durability supports planned IND/BLA filings, pivotal planning and early commercialization activities without immediate equity dilution risk.
Negative Factors
High cash burn
Sustained negative operating and free cash flows mean the company remains dependent on external financing and milestone-based facilities. Conditional funding and eventual principal repayment obligations can constrain strategic flexibility and may force dilutive raises or restrictive covenants over time.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash runway
A large cash balance plus a structured $500M facility materially reduces near-term financing pressure and permits multi-program execution. This durability supports planned IND/BLA filings, pivotal planning and early commercialization activities without immediate equity dilution risk.
Read all positive factors
Beam Therapeutics (BEAM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.49B
Dividend YieldN/A
Average Volume (3M)2.13M
Price to Earnings (P/E)―
Beta (1Y)2.11
Revenue Growth-84.07%
EPS Growth-157.71%
CountryUS
Employees393
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)2.33
Shares Outstanding101,856,250
10 Day Avg. Volume2,483,725
30 Day Avg. Volume2,131,635
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.21
Price to Sales (P/S)19.62
P/FCF Ratio-7.61
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue17.84
Enterprise Value/Gross Profit-14.15
Enterprise Value/Ebitda-33.27
Forecast
1Y Price Target
$48.38Price Target Upside99.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-4.38
Revenue Forecast (FY)$44.64M
Beam Therapeutics Business Overview & Revenue Model
Company Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassem...
How the Company Makes Money
Beam Therapeutics makes money primarily through (1) collaboration and licensing revenue from strategic partnerships and (2) operating cash and investment income; it may also generate smaller amounts of other revenue (e.g., grants) depending on the...
Beam Therapeutics Earnings Call Summary
Earnings Call Date:Feb 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call presented substantial positive momentum: a new liver-targeted PKU program with strong preclinical efficacy, constructive FDA engagement around an umbrella platform approach, demonstrated LNP and manufacturing capabilities, and a major non-dilutive financing that extends runway into mid-2029. Key risks highlighted include regulatory ambiguity for novel individualized pathways, the large diversity of PAH variants (necessitating personalized approaches), limited public detail on bystander/off-target profiles, and conditional milestone-based financing. On balance, the updates emphasize progress, resources, and clear near-term milestones while acknowledging technical and regulatory uncertainties that are typical for platform-based gene editing development.Positive Updates
New PKU Program (BEAM-304) Initiated and Rapidly Advanced
Beam announced BEAM-304, a liver-targeted base editing program for phenylketonuria (PKU). The company identified two development candidates (including R408W) that together could treat nearly half (~50%) of PKU patients in the U.S. Initial IND-enabling work was advanced in under 2 years with an IND planned to be filed in 2026.
Negative Updates
Regulatory Ambiguity Around 'Plausible Mechanism' Pathway
Draft FDA guidance on the plausible mechanism pathway remains ambiguous about which diseases/variants qualify (ultra-rare vs. more common variants). Beam indicated the framework could help but final applicability to PKU (with both frequent and ultra-rare variants) is uncertain and will require case-by-case discussions with regulators.
Read all updates
Q4-2025 Updates
Positive
Negative
New PKU Program (BEAM-304) Initiated and Rapidly Advanced
Beam announced BEAM-304, a liver-targeted base editing program for phenylketonuria (PKU). The company identified two development candidates (including R408W) that together could treat nearly half (~50%) of PKU patients in the U.S. Initial IND-enabling work was advanced in under 2 years with an IND planned to be filed in 2026.
Read all positive updates
Company Guidance
Beam provided clear program and financial guidance: Beam plans to file the BEAM‑304 IND in 2026 and initiate an open‑label, single‑ascending‑dose Phase I/II in R408W, expects to report updated BEAM‑302 Phase I/II data and a pivotal plan this quarter and to submit the risto‑cel BLA as early as year‑end 2026, and also expects to report initial BEAM‑301 GSDIa data, complete the BEAM‑103 healthy volunteer study and advance in‑vivo HSC editing during 2026. Financially, Beam ended 2025 with $1.25 billion in cash/cash equivalents/marketable securities and announced a Sixth Street facility up to $500 million ( $100M funded at close, up to $300M tied to regulatory/clinical/commercial milestones, plus $100M subject to mutual agreement over a 7‑year term), with a minimum draw of $200M expected to extend runway into mid‑2029 and principal repayment due early 2033. Key program metrics highlighted include two BEAM‑304 candidates that could address nearly half of ~20,000 U.S. PKU patients, preclinical single‑dose (0.3 mg/kg) LNP results that normalized plasma phenylalanine below the 360 µM therapeutic threshold by day 7 in R408W and a second mutation model, and recognition of >1,000 PAH variants worldwide supporting an umbrella/multi‑variant IND approach.Beam Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 139.74M | 63.52M | 377.71M | 60.92M | 51.84M |
| Gross Profit | 117.45M | -304.04M | 377.71M | -250.67M | -180.29M |
| EBITDA | -29.92M | -393.64M | -146.95M | -324.33M | -230.06M |
| Net Income | -79.99M | -376.74M | -132.53M | -289.09M | -370.64M |
Balance Sheet | |||||
| Total Assets | 1.48B | 1.10B | 1.46B | 1.34B | 1.47B |
| Cash, Cash Equivalents and Short-Term Investments | 1.25B | 850.74M | 1.19B | 1.08B | 965.65M |
| Total Debt | 293.88M | 161.43M | 172.69M | 179.00M | 147.64M |
| Total Liabilities | 242.82M | 370.28M | 478.38M | 608.24M | 647.72M |
| Stockholders Equity | 1.24B | 733.54M | 981.33M | 733.47M | 826.74M |
Cash Flow | |||||
| Free Cash Flow | -360.05M | -356.19M | -182.93M | -26.42M | -113.08M |
| Operating Cash Flow | -345.10M | -347.25M | -149.19M | 22.53M | -66.27M |
| Investing Cash Flow | -121.44M | 185.01M | 71.84M | -461.34M | -294.14M |
| Financing Cash Flow | 478.05M | 7.74M | 276.45M | 111.59M | 756.14M |
Beam Therapeutics Technical Analysis
Neutral
24.23
Price Trends
26.71
Negative
26.75
Negative
24.04
Positive
Market Momentum
-0.93
Negative
45.39
Neutral
68.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BEAM, the sentiment is Neutral. The current price of 24.23 is below the 20-day moving average (MA) of 24.69, below the 50-day MA of 26.71, and above the 200-day MA of 24.04, indicating a neutral trend. The MACD of -0.93 indicates Negative momentum. The RSI at 45.39 is Neutral, neither overbought nor oversold. The STOCH value of 68.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BEAM.
Beam Therapeutics Risk Analysis
Beam Therapeutics disclosed 86 risk factors in its most recent earnings report. Beam Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Beam Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $2.89B | -228.91 | -10.26% | ― | 129.21% | 80.35% | |
62 Neutral | $5.01B | -10.43 | -65.80% | ― | ― | -27.70% | |
54 Neutral | $2.49B | -34.27 | -7.31% | ― | -84.07% | -157.71% | |
53 Neutral | $1.62B | -19.61 | -6.93% | ― | 27.51% | 38.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $3.08B | -5.65 | -50.13% | ― | ― | -5.30% | |
43 Neutral | $2.55B | -13.21 | -32.80% | ― | ― | -34.96% |
* Healthcare Sector Average
BEAM
Beam Therapeutics
24.49
9.95
68.43%
DNLI
Denali Therapeutics
19.41
7.94
69.22%
IMVT
Immunovant
24.61
11.30
84.90%
ARQT
Arcutis Biotherapeutics
23.27
9.98
75.09%
IRON
Disc Medicine
66.85
32.57
95.01%
IMCR
Immunocore Holdings
31.96
7.43
30.29%
Beam Therapeutics Corporate Events
Business Operations and Strategy
Beam Therapeutics Restructures Base-Editing Licensing After Bio Palette Exit
Positive
Mar 5, 2026
On March 2, 2026, Beam Therapeutics Inc. and Japan-based Bio Palette Co., Ltd. mutually terminated their 2019 cross-license agreement covering base-editing and gene-editing patents, in connection with the planned dissolution of Bio Palette. Under ...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Beam Therapeutics Secures $500 Million Credit Facility
Positive
Feb 24, 2026
On February 24, 2026, Beam Therapeutics reported fourth-quarter and full-year 2025 financial results, showing cash, cash equivalents and marketable securities of $1.25 billion at year-end, up from $850.7 million a year earlier, alongside higher an...
Business Operations and Strategy
Beam Therapeutics Secures Standby License for Key Patents
Positive
Feb 12, 2026
On February 9, 2026, Beam Therapeutics entered into a standby license agreement with Kobe University and Bio Palette Co., Ltd. to secure continued access to certain gene-editing patents originally licensed by Bio Palette from Kobe. The arrangement...
Executive/Board Changes
Beam Therapeutics announces upcoming board member resignation
Neutral
Feb 5, 2026
On January 31, 2026, Beam Therapeutics Inc. announced that board member Dr. Carole Ho had submitted her resignation from the company’s Board of Directors, effective February 27, 2026. The company noted that Dr. Ho’s departure was not d...
Business Operations and StrategyFinancial Disclosures
Beam Therapeutics outlines 2026 strategy and extends runway
Positive
Jan 12, 2026
On January 11, 2026, Beam Therapeutics outlined strategic priorities for 2026 across its genetic disease and hematology franchises, emphasizing progress in late-stage clinical programs and a substantially extended cash runway. The company reported...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.